Vaxcyte, Inc. PCVX Business Segments — G&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s business segments — g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s business segments — G&A?
- Vaxcyte, Inc. (PCVX) reported business segments — G&A of $33.07M in Q1 2026.
- How has Vaxcyte, Inc.'s business segments — G&A changed year-over-year?
- Vaxcyte, Inc.'s business segments — G&A increased by 1.3% year-over-year, from $32.66M to $33.07M.
- What is the long-term trend for Vaxcyte, Inc.'s business segments — G&A?
- Over 3 years (2022 to 2025), Vaxcyte, Inc.'s business segments — G&A has grown at a 48.1% compound annual growth rate (CAGR), from $39.81M to $129.37M.
- What does business segments — G&A mean?
- This metric captures the overhead costs associated with the daily operations of the business segment, including executive compensation, legal, finance, and other corporate support functions. It serves as a measure of the operational efficiency and administrative burden required to sustain the segment's activities. Monitoring this helps assess the scalability of the organization's infrastructure.